low - Prescription pharmaceutical demand is largely non-discretionary and driven by disease prevalence rather than GDP. However, Aesthetics segment (12-15% of revenue) is highly cyclical as Botox and filler procedures are elective and correlate with consumer confidence and discretionary spending. Immunology and oncology revenues remain stable through recessions.

Rising rates increase debt service costs on AbbVie's $93B debt load (legacy from Allergan acquisition), though the company generates strong operating cash flow ($20B+ annually) to service obligations. Higher rates also compress valuation multiples for dividend-paying biopharma stocks, as AbbVie's 3.5% yield becomes less attractive versus risk-free alternatives. Refinancing risk is manageable with staggered maturities.

dividend - AbbVie offers a 3.5% dividend yield with 52 consecutive years of increases (Dividend Aristocrat status), attracting income-focused investors. Also appeals to value investors during patent transition periods when stock trades at discounted multiples (current 16.7x EV/EBITDA below historical average). Growth investors focus on Skyrizi/Rinvoq trajectory offsetting Humira decline.